Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2633MR)

This product GTTS-WQ2633MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2633MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5486MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ9790MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ2051MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10211MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4822MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ13348MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ13441MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ7192MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW